CL2012002882A1 - Compuestos derivados de 5,7- sustituido -imidazol [1,2-c] pirimidinas, inhibidores de jak-quinasa; proceso de preparacion; composicion farmaceutica; y su uso para tratar una enfermedad autoinmunitaria o inflamatoria, el rechazo de transplante de organos, tejidos o celulas en un mamifero. - Google Patents

Compuestos derivados de 5,7- sustituido -imidazol [1,2-c] pirimidinas, inhibidores de jak-quinasa; proceso de preparacion; composicion farmaceutica; y su uso para tratar una enfermedad autoinmunitaria o inflamatoria, el rechazo de transplante de organos, tejidos o celulas en un mamifero.

Info

Publication number
CL2012002882A1
CL2012002882A1 CL2012002882A CL2012002882A CL2012002882A1 CL 2012002882 A1 CL2012002882 A1 CL 2012002882A1 CL 2012002882 A CL2012002882 A CL 2012002882A CL 2012002882 A CL2012002882 A CL 2012002882A CL 2012002882 A1 CL2012002882 A1 CL 2012002882A1
Authority
CL
Chile
Prior art keywords
pyrimidines
mammal
organs
tissues
substituted
Prior art date
Application number
CL2012002882A
Other languages
English (en)
Spanish (es)
Inventor
Mark Laurence Boys
Robert D Groneberg
Darren M Harvey
Lily Huang
Timothy Kercher
Christopher F Kraser
Ellen Laird
Eugene Tarlton
Qian Zhao
Laurence E Burgess
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of CL2012002882A1 publication Critical patent/CL2012002882A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CL2012002882A 2010-04-14 2012-10-12 Compuestos derivados de 5,7- sustituido -imidazol [1,2-c] pirimidinas, inhibidores de jak-quinasa; proceso de preparacion; composicion farmaceutica; y su uso para tratar una enfermedad autoinmunitaria o inflamatoria, el rechazo de transplante de organos, tejidos o celulas en un mamifero. CL2012002882A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US32418610P 2010-04-14 2010-04-14

Publications (1)

Publication Number Publication Date
CL2012002882A1 true CL2012002882A1 (es) 2013-02-08

Family

ID=43984073

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012002882A CL2012002882A1 (es) 2010-04-14 2012-10-12 Compuestos derivados de 5,7- sustituido -imidazol [1,2-c] pirimidinas, inhibidores de jak-quinasa; proceso de preparacion; composicion farmaceutica; y su uso para tratar una enfermedad autoinmunitaria o inflamatoria, el rechazo de transplante de organos, tejidos o celulas en un mamifero.

Country Status (21)

Country Link
US (1) US8962596B2 (enExample)
EP (1) EP2558468B1 (enExample)
JP (2) JP2013523884A (enExample)
KR (1) KR20130094710A (enExample)
CN (1) CN102985424B (enExample)
AR (1) AR081075A1 (enExample)
AU (1) AU2011240808B2 (enExample)
CA (1) CA2796388A1 (enExample)
CL (1) CL2012002882A1 (enExample)
CO (1) CO6630187A2 (enExample)
CR (1) CR20120572A (enExample)
MX (1) MX2012011941A (enExample)
NZ (1) NZ603446A (enExample)
PH (1) PH12012502046A1 (enExample)
RU (1) RU2012148246A (enExample)
SG (1) SG184870A1 (enExample)
TW (1) TWI494314B (enExample)
UA (1) UA109131C2 (enExample)
UY (1) UY33328A (enExample)
WO (1) WO2011130146A1 (enExample)
ZA (1) ZA201208544B (enExample)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA116187C2 (uk) 2005-12-13 2018-02-26 Інсайт Холдінгс Корпорейшн ГЕТЕРОАРИЛЗАМІЩЕНІ ПІРОЛО[2,3-b]ПІРИДИНИ Й ПІРОЛО[2,3-b]ПІРИМІДИНИ ЯК ІНГІБІТОРИ ЯНУС-КІНАЗИ
WO2008157208A2 (en) 2007-06-13 2008-12-24 Incyte Corporation Salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
PE20120371A1 (es) 2009-05-22 2012-05-17 Incyte Corp 3-[4-(7h-pirrolo[2,3-d]pirimidin-4il)-1h-pirazol-1-il]octano o heptano-nitrilo como inhibidores de jak
EP2432555B1 (en) 2009-05-22 2014-04-30 Incyte Corporation N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
PL2442809T3 (pl) 2009-06-17 2017-02-28 Vertex Pharmaceuticals Incorporated Inhibitory replikacji wirusów grypy
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
DK3354652T3 (da) 2010-03-10 2020-05-18 Incyte Holdings Corp Piperidin-4-yl azetidinderivativer som jak1-inhibitorer
PE20130216A1 (es) 2010-05-21 2013-02-27 Incyte Corp Formulacion topica para un inhibidor de jak
PH12013501001A1 (en) 2010-11-19 2019-09-02 Incyte Holdings Corp Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
EP2640725B1 (en) 2010-11-19 2015-01-07 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
AU2011343642A1 (en) 2010-12-16 2013-05-02 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
AR086983A1 (es) 2011-06-20 2014-02-05 Incyte Corp Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
AU2012323399A1 (en) * 2011-10-12 2014-05-29 Array Biopharma Inc. 5,7-substituted-imidazo[1,2-c]pyrimidines
WO2013070606A1 (en) * 2011-11-07 2013-05-16 Vertex Pharmaceuticals Incorporated Methods for treating inflammatory diseases and pharmaceutical combinations useful therefor
AR091079A1 (es) 2012-05-18 2014-12-30 Incyte Corp Derivados de pirrolopirimidina y pirrolopiridina sustituida con piperidinilciclobutilo como inhibidores de jak
EP2912031B1 (en) 2012-10-24 2017-05-31 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
NZ708157A (en) 2012-11-15 2019-07-26 Incyte Holdings Corp Sustained-release dosage forms of ruxolitinib
WO2014118388A1 (en) 2013-02-04 2014-08-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for assaying jak2 activity in red blood cells and uses thereof
SMT201900081T1 (it) * 2013-03-06 2019-05-10 Incyte Holdings Corp Procedimenti e intermedi per produrre un inibitore di jak
WO2014146249A1 (en) 2013-03-19 2014-09-25 Merck Sharp & Dohme Corp. Geminally substituted cyanoethylpyrazolo pyridones as janus kinase inhibitors
US9637483B2 (en) 2013-03-28 2017-05-02 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2014172639A1 (en) * 2013-04-19 2014-10-23 Ruga Corporation Raf kinase inhibitors
PE20200527A1 (es) 2013-05-17 2020-03-09 Incyte Corp Derivados del bipirazol como inhibidores jak
HRP20200955T1 (hr) 2013-08-07 2020-10-02 Incyte Corporation Dozni oblici s produženim oslobađanjem za jak1 inhibitor
EP3421468B1 (en) 2013-11-13 2020-11-04 Vertex Pharmaceuticals Incorporated Methods of preparing inhibitors of influenza viruses replication
LT3068776T (lt) 2013-11-13 2019-08-12 Vertex Pharmaceuticals Incorporated Gripo virusų replikacijos inhibitoriai
WO2015184305A1 (en) 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
USRE49517E1 (en) 2014-08-15 2023-05-02 Janssen Pharmaceuticals, Inc. Pyrazoles
RU2021102805A (ru) 2014-12-05 2021-02-12 Эррэй Биофарма Инк. 4,6-ЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-a]ПИРАЗИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ
CN105777754B (zh) * 2014-12-16 2019-07-26 北京赛林泰医药技术有限公司 吡咯并嘧啶化合物
ES2962330T3 (es) 2015-01-20 2024-03-18 Wuxi Fortune Pharmaceutical Co Ltd Inhibidor de jak
PL3290418T3 (pl) * 2015-04-29 2019-11-29 Wuxi Fortune Pharmaceutical Co Ltd Inhibitory kinaz janusowych (jak)
WO2016183120A1 (en) 2015-05-13 2016-11-17 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
JP6704416B2 (ja) 2015-05-13 2020-06-03 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ インフルエンザウイルスの複製の阻害剤を調製する方法
PT3305788T (pt) 2015-05-29 2020-09-25 Wuxi Fortune Pharmaceutical Co Ltd Inibidor da janus cinase
AR104918A1 (es) * 2015-06-19 2017-08-23 Lilly Co Eli Procesos e intermediarios para la preparación de {1-(etilsulfonil)-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]azetidin-3-il}acetonitrilo
CN105294699B (zh) * 2015-12-04 2019-06-11 上海勋和医药科技有限公司 巴瑞替尼的制备方法
EP3409673B1 (en) 2016-01-26 2021-06-16 Hangzhou Bangshun Pharmaceutical Co., Ltd. Pyrrolopyrimidine five-membered azacyclic derivative and application thereof
AU2017222417B2 (en) 2016-02-24 2020-07-09 Pfizer Inc. Pyrazolo[1,5-a]pyrazin-4-yl derivatives as JAK-inhibitors
KR102485731B1 (ko) 2017-01-23 2023-01-05 상하이 롱우드 바이오파마슈티칼스 컴퍼니 리미티드 Jak 효소 억제제 및 이의 제조 방법과 용도
WO2018167283A1 (en) 2017-03-17 2018-09-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling
US20200088732A1 (en) 2017-04-13 2020-03-19 INSERM (Institut National de la Santé et de la Recherche Mèdicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma
JP7365332B2 (ja) 2017-08-07 2023-10-19 ジョイント・ストック・カンパニー “バイオキャド” Ｃｄｋ８／１９阻害薬としての新規ヘテロ環式化合物
US11254668B2 (en) 2017-08-14 2022-02-22 Pfizer Inc. Pyrazolo[1,5-A]pyrazin-4-yl and related derivatives
AR113922A1 (es) 2017-12-08 2020-07-01 Incyte Corp Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
IL276302B2 (en) 2018-01-30 2023-11-01 Incyte Corp Procedures for preparing [1-(3-fluoro-2-(trifluoromethyl(isonicotinyl}piperidine-4-one)
KR20240157777A (ko) 2018-02-16 2024-11-01 인사이트 코포레이션 사이토카인-관련 장애의 치료를 위한 jak1 경로 억제제
EP4424328A3 (en) 2018-03-30 2024-12-04 Incyte Corporation Treatment of hidradenitis suppurativa using jak inhibitors
US20220041588A1 (en) * 2018-09-27 2022-02-10 Fochon Pharmaceuticals, Ltd. Substituted imidazo[1,2-a]pyridine and [1,2,4]triazolo[1,5-a]pyridine compounds as ret kinase inhibitors
TWI721624B (zh) 2018-10-31 2021-03-11 美商基利科學股份有限公司 經取代之6-氮雜苯并咪唑化合物
ES2979163T3 (es) 2018-10-31 2024-09-24 Gilead Sciences Inc Compuestos de 6-azabenzimidazol sustituidos como inhibidores de HPK1
WO2020092015A1 (en) 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection
CN111320624B (zh) * 2018-12-14 2023-05-12 中国医药研究开发中心有限公司 三唑并吡啶类和咪唑并吡啶类化合物及其制备方法和医药用途
ES2981909T3 (es) * 2019-04-12 2024-10-11 Primegene Beijing Co Ltd Compuestos derivados de pirazolopirazina, composición farmacéutica y utilización de los mismos
US11453681B2 (en) 2019-05-23 2022-09-27 Gilead Sciences, Inc. Substituted eneoxindoles and uses thereof
CN111039963B (zh) * 2019-12-31 2021-03-19 卓和药业集团有限公司 Wxfl10203614水溶性类似物及其合成方法
BR112022024632A2 (pt) 2020-06-02 2023-02-28 Incyte Corp Processos para preparar um inibidor de jak1
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
EP3944859A1 (en) 2020-07-30 2022-02-02 Assistance Publique Hôpitaux de Paris Method for treating immune toxicities induced by immune checkpoint inhibitors
US11957661B2 (en) 2020-12-08 2024-04-16 Incyte Corporation JAK1 pathway inhibitors for the treatment of vitiligo
CA3219092A1 (en) 2021-05-03 2022-11-10 Incyte Corporation Jak1 pathway inhibitors for the treatment of prurigo nodularis
US20250011332A1 (en) * 2021-11-12 2025-01-09 Soter Biopharma Pte. Ltd. Pyrazolo fused ring compound and use thereof
US20250263409A1 (en) * 2022-04-25 2025-08-21 Eli Lilly And Company Fgfr2 inhibitor compounds

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728536A (en) 1993-07-29 1998-03-17 St. Jude Children's Research Hospital Jak kinases and regulation of Cytokine signal transduction
HUP0103386A3 (en) 1998-08-21 2002-07-29 Parker Hughes Inst St Paul Use of quinazoline derivatives for producing pharmaceutical compositions having jak 3-inhibitor effect
JP2001302667A (ja) * 2000-04-28 2001-10-31 Bayer Ag イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体
WO2006044687A2 (en) * 2004-10-15 2006-04-27 Takeda San Diego, Inc. Kinase inhibitors
UA116187C2 (uk) 2005-12-13 2018-02-26 Інсайт Холдінгс Корпорейшн ГЕТЕРОАРИЛЗАМІЩЕНІ ПІРОЛО[2,3-b]ПІРИДИНИ Й ПІРОЛО[2,3-b]ПІРИМІДИНИ ЯК ІНГІБІТОРИ ЯНУС-КІНАЗИ
AU2007323725B2 (en) * 2006-11-22 2014-02-20 Incyte Holdings Corporation Imidazotriazines and imidazopyrimidines as kinase inhibitors
DE102007012645A1 (de) * 2007-03-16 2008-09-18 Bayer Healthcare Ag Substituierte Imidazo- und Triazolopyrimidine
CL2008001709A1 (es) * 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
NZ587928A (en) 2008-03-11 2012-08-31 Incyte Corp Azetidine and cyclobutane derivatives as jak inhibitors
JOP20190231A1 (ar) 2009-01-15 2017-06-16 Incyte Corp طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به

Also Published As

Publication number Publication date
PH12012502046A1 (en) 2017-07-26
EP2558468B1 (en) 2015-04-01
NZ603446A (en) 2014-05-30
CN102985424B (zh) 2015-03-11
AU2011240808B2 (en) 2015-01-22
CN102985424A (zh) 2013-03-20
JP2015205905A (ja) 2015-11-19
EP2558468A1 (en) 2013-02-20
TW201134827A (en) 2011-10-16
US20130131039A1 (en) 2013-05-23
JP2013523884A (ja) 2013-06-17
AU2011240808A1 (en) 2012-11-29
KR20130094710A (ko) 2013-08-26
SG184870A1 (en) 2012-11-29
WO2011130146A1 (en) 2011-10-20
US8962596B2 (en) 2015-02-24
AR081075A1 (es) 2012-06-06
TWI494314B (zh) 2015-08-01
CA2796388A1 (en) 2011-10-20
RU2012148246A (ru) 2014-05-20
CO6630187A2 (es) 2013-03-01
UY33328A (es) 2012-10-31
UA109131C2 (ru) 2015-07-27
CR20120572A (es) 2013-02-20
ZA201208544B (en) 2015-04-29
MX2012011941A (es) 2013-08-27

Similar Documents

Publication Publication Date Title
CL2012002882A1 (es) Compuestos derivados de 5,7- sustituido -imidazol [1,2-c] pirimidinas, inhibidores de jak-quinasa; proceso de preparacion; composicion farmaceutica; y su uso para tratar una enfermedad autoinmunitaria o inflamatoria, el rechazo de transplante de organos, tejidos o celulas en un mamifero.
CL2011002115A1 (es) Compuestos derivados de 5-fenil-1h-piridin-2-ona y 5-fenil-pirazin-2-ona, inhibidores de la tirosina-quinasa de bruton (btk); proceso de preparación de los compuestos, compuesto intermediario, composición farmacéutica y uso en el tratamiento de enfermedades inflamatorias y/o autoinmunes.
CL2014000931A1 (es) Compuestos derivados de 5,7-imidazo[1,2-c]pirimidina sustituida, inhibidores de las cinasas jak; proceso de preparacion; composicion farmaceutica; metodo para el tratamiento de enfermedades autoinmunitarias, inflamatorias, rechazo de trasplante de organos y neoplasias.
CL2012001379A1 (es) Compuestos derivados de imidazopiridina, inhibidores de jak; composición farmacéutica; combinación farmacéutica; y uso en trastornos mieloproliferativos, leucemia, tumores sólidos, rechazo de trasplantes de médula ósea y órganos, entre otras.
MX2012004881A (es) Metodos para reprogramar células y sus usos.
CL2016001055A1 (es) Compuestos derivados de fenil-aminopirimidina, inhibidores de la tirosina quinasa de bruton (btk), composicion farmaceutica; combinacion farmaceutica; útiles en el tratamiento de enfermedades autoinmunes, inflamatorias, alergicas, de las vias aereas, entre otras.
CU20120084A7 (es) Compuestos derivados de triazolopiridina sustituidos como inhibidores de la quinasa mps-1 y compuestos intermediarios para su preparación
CL2011002956A1 (es) Compuestos derivados de pirrolo[2,3-d]pirimidina, inhibidores de la quinasa janus (jak1); composicion farmaceutica; y uso para el tratamiento de una enfermedad autoinmune, cancer, trastorno mieloproliferativo, una enfermedad inflamatoria o rechazo de trasplante de organos.
AR079889A1 (es) Antagonistas de wnt y metodos de tratamiento y deteccion
CL2008001659A1 (es) Compuestos derivados de quinoxalina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar una enfermedad inmunologica seleccionada a partir de rechazo de trasplante de organo, lupus, esclerosis multiple, entre otras enfermedades.
CR20110470A (es) Proteínas de union a il-17
BRPI0815052A2 (pt) Diferenciação de células-tronco pluripotentes por meio de uso de células nutrizes humanas
EA201101666A1 (ru) 3-[4-(7H-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)-1H-ПИРАЗОЛ-1-ИЛ]ОКТАН- ИЛИ ГЕПТАННИТРИЛ КАК JAK-ИНГИБИТОРЫ
IN2015DN00017A (enExample)
UA107935C2 (xx) 5-феніл-$1,2,4]триазоло$1,5-а]піридин-2-ілкарбоксаміди як інгібітори jak
SV2011003888A (es) Compuestos que expanden las celulas madre hematopoieticas
ECSP10010548A (es) Composiciones y metodos de preparacion y uso de las mismas
EP4403197A3 (en) Injectable formulations for organ augmentation
EA201390010A1 (ru) Замещенные триазолопиридины
CL2011003022A1 (es) Compuestos derivados de 2,4 diaminopirimidina, inhibidores de quinasa ptk2; composicion farmaceutica que comprende a uno de los compuestos, utiles en el tratamiento de enfermedades que se caracterizan por una proliferacion celular excesiva, tal como cancer.
CO6761392A2 (es) Administración de proteínas a partir de microportadores de células madre
CL2007001711A1 (es) Compuestos derivados de pirazolopiridina sustituida;composicion farmaceutica que los comprende;metodo de preparacion de los compuestos ,compuestos intermediarios;y su uso en el tratamiento de enfermedades,tales como tumores,artritis reumatoide,enfermedades del crecimiento vascular desregulado, entre otras.
CL2011000195A1 (es) Compuestos derivados de 5-alquinil-pirimidina, inhibidores de quinasas; composiciones farmaceuticas que comprenden a los compuestos; y uso de los compuestos en la preparacion de medicamentos para el tratamiento del cancer.
WO2017015245A8 (en) Methods and compositions for stem cell transplantation
WO2016048861A3 (en) Heterocyclic compounds and use thereof